The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Total Income in Q2 FY25 stood at Rs. 532.18 crore
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Subscribe To Our Newsletter & Stay Updated